Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., . . . Verstovsek, S. (2018). Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol.
Citación estilo ChicagoMascarenhas, John, et al. "Pacritinib Vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial." JAMA Oncol 2018.
Cita MLAMascarenhas, John, et al. "Pacritinib Vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial." JAMA Oncol 2018.
Precaución: Estas citas no son 100% exactas.